<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04669418</url>
  </required_header>
  <id_info>
    <org_study_id>H-2-2010-002_1</org_study_id>
    <nct_id>NCT04669418</nct_id>
  </id_info>
  <brief_title>Host RNA Signature in Children With Cancer and Infection</brief_title>
  <official_title>Host RNA Signature to Discriminate Bacterial From Viral Infection and Non-specific Inflammation in Children With Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rigshospitalet, Denmark</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Børnecancerfonden</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Lundbeck Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Danish Cancer Society</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Rigshospitalet, Denmark</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim is to investigate if RNA expression signature can discriminate bacterial from viral&#xD;
      infection or non-infectious inflammation in children with cancer.&#xD;
&#xD;
      Earlier studies in immunocompetent children have shown promising results, but studies in&#xD;
      immunocompromised children are lacking.&#xD;
&#xD;
      We aim to include 300 febrile episodes in children with cancer. The samples will be analysed&#xD;
      by RNA sequencing. If succesfull, this method can help prevent unnecessary antibiotic&#xD;
      treatment, reduce hospital admissions, side effects and antimicrobial resistance and improve&#xD;
      quality of life for children during cancer treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Children with cancer are at high risk of invasive bacterial infections particularly during&#xD;
      neutropenia. Febrile neutropenia is an early sign of a potentially fatal infection requiring&#xD;
      broad-spectrum empiric antibiotics. However, the majority of children do not have a bacterial&#xD;
      infection, but still receive antibiotics, since current tests cannot distinguish causes of&#xD;
      fever. A number of transcriptomic studies of immunocompetent patients show that host&#xD;
      leukocyte patterns of activated RNA can discriminate bacterial infection from non-infectious&#xD;
      inflammation with high accuracy, but studies in immunocomprised patients are few.&#xD;
&#xD;
      Methods&#xD;
&#xD;
      A prospective non-interventional observational multicentre study including febrile childhood&#xD;
      cancer patients during 24 months at all Danish Pediatric Oncology Departments&#xD;
      (Rigshospitalet, Aarhus, Odense and Aalborg University Hospitals). Leukocyte RNA expression&#xD;
      will be analysed in whole blood samples by RNA sequencing adjusted for low RNA input. 300&#xD;
      febrile episodes will be included, and predictive host RNA signatures will be identified in a&#xD;
      discovery cohort and assessed in a validation cohort. Further, to explore the transcriptome&#xD;
      in non-febrile children with neutropenia, we include a control group of 15 children with&#xD;
      cancer and no fever.&#xD;
&#xD;
      Time frame Inclusion of children: 1st of June 2019 to 31st of May 2021 Analysis of samples&#xD;
      (RNA sequencing): 1st of June 2021 - 1st of December 2021&#xD;
&#xD;
      Perspective&#xD;
&#xD;
      The study will create a base for a randomised trial regarding implementation of RNA signature&#xD;
      versus normal procedure in handling febrile children with cancer. This can lead to the&#xD;
      development of a targeted RNA-expression analytical platform that can prevent unnecessary&#xD;
      antibiotic treatment in the majority of children with febrile neutropenia. This will reduce&#xD;
      hospital admissions, side effects, antimicrobial resistance and improve quality of life&#xD;
      during cancer treatment. The results can be extrapolated to the adult patients with cancer,&#xD;
      who are often treated with prophylactic antibiotics, which complicate finding the infectious&#xD;
      agent. Additionally, the test may be applied in other immunosuppressed children with&#xD;
      infections.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 1, 2019</start_date>
  <completion_date type="Anticipated">July 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>RNA signature</measure>
    <time_frame>1.5 years</time_frame>
    <description>To detect specific RNA signatures in whole blood in children with febrile neutropenia</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time study</measure>
    <time_frame>1,5 years</time_frame>
    <description>An investigation of the change in RNA expression over time during an infection period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Application of known RNA signatures</measure>
    <time_frame>1,5 years</time_frame>
    <description>To test RNA signatures from genes published in other studies eg. the genes IFI44L and FAM89A</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Differences in RNA signature according to pathogen</measure>
    <time_frame>1,5 years</time_frame>
    <description>To investigate potential differences in RNA signatures in patients with gram positive versus gram negative bacteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparishment of RNA signatures in neutropenic and non-neutropenic children</measure>
    <time_frame>1,5 years</time_frame>
    <description>To compare RNA signatures in febrile neutropenic and non-neutropenic children with a positive blood culture</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Childhood Cancer</condition>
  <condition>Infection</condition>
  <condition>Neutropenia, Febrile</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <description>70 children with cancer and a positive blood culture.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <description>50 children with cancer and no positive blood culture.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>RNA expression signature</intervention_name>
    <description>Whole transcriptome profiling using RNA sequencing</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      All children will have 2.5 ml whole blood drawn into a PaxGene RNA (Qiagen®) tube along with&#xD;
      routine blood tests. Only RNA is extracted&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Children with cancer and fever admitted to the Pediatric Oncology Departments throughout&#xD;
        Denmark.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Children with cancer and fever. Fever defined as temperature above 38.5 °C measured once,&#xD;
        or 38.0-38.5 °C for ≥ 1 hour.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        The children can be excluded if they turn out to have a different diagnosis than expected&#xD;
        or if it is not possible to draw the blood tests.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lotte M. Smedegaard, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>ph.d.-student</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lotte M. Smedegaard, M.D.</last_name>
    <phone>+ 45 26215766</phone>
    <email>lotte.moeller.smedegaard@regionh.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ulrikka Nygaard, M.D., ph.d.</last_name>
    <phone>+ 45 35459761</phone>
    <email>ulrikka.nygaard@regionh.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Pediatrics, Aalborg University Hospital</name>
      <address>
        <city>Aalborg</city>
        <zip>9000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ruta Tuckuviene, M.D.</last_name>
      <email>rt@rn.dk</email>
    </contact>
    <contact_backup>
      <last_name>Naja Panduro, Nurse</last_name>
      <email>napa@rn.dk</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Department of Pediatric Oncology, Aarhus University Hospital</name>
      <address>
        <city>Aarhus</city>
        <zip>8200</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ines Kristensen, M.D., ph.d.</last_name>
      <email>inekri@rm.dk</email>
    </contact>
    <contact_backup>
      <last_name>Kamilla Tofting-Olesen, Nurse</last_name>
      <email>kaminiel@rm.dk</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Center for Genomic Medicine</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olga Østrup, MSc, ph.d.</last_name>
      <email>olga.oestrup@regionh.dk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Department of pediatric and adolescent medicine, Rigshospitalet (Copenhagen University Hospital)</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lotte M Smedegaard, M.D.</last_name>
      <phone>+45 26215766</phone>
      <email>lotte.moeller.smedegaard@regionh.dk</email>
    </contact>
    <contact_backup>
      <last_name>Ulrikka Nygaard, M.D., ph.d.</last_name>
      <phone>+45 35 45 9761</phone>
      <email>ulrikka.nygaard@regionh.dk</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Department of Pediatrics, The H.C. Andersen's Children's hospital</name>
      <address>
        <city>Odense</city>
        <zip>5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dorthe Grosen, M.D., ph.d.</last_name>
      <email>dorthe.grosen@rsyd.dk</email>
    </contact>
    <contact_backup>
      <last_name>Hilde D. Galsgaard, Nurse</last_name>
      <email>hilde.galsgaard@rsyd.dk</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>December 9, 2020</study_first_submitted>
  <study_first_submitted_qc>December 9, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 16, 2020</study_first_posted>
  <last_update_submitted>December 9, 2020</last_update_submitted>
  <last_update_submitted_qc>December 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Rigshospitalet, Denmark</investigator_affiliation>
    <investigator_full_name>Lotte Møller Smedegaard</investigator_full_name>
    <investigator_title>M.D.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Neutropenia</mesh_term>
    <mesh_term>Febrile Neutropenia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

